Approval Probability
TA Base Rate
Adjusted LOA
ML Risk
Bone Morphogenetic Protein 2 · 1 trial · 3 indications
Radiological signs of healing is a criteria for a successful result. Failure of healing after 6 months and/or a need for stimulant bone healing intervention can result in: * Dynamic measurement af immobilization * Ultrasound stimulation * Re-surgery with application of bone graft or bone replacement
| Arm | Type | Description |
|---|---|---|
| Bone Morphogenetic Protein 2 | EXPERIMENTAL | Condition of bone healing will be evaluated at serial radiological examinations and by clinical results according to a standard score system. |
| Autologous bone graft | EXPERIMENTAL | Condition of bone healing will be evaluated at serial radiological examinations after 1,2,3,4,5,6,9 and 12 months. Blood tests and urine samples will also be examined for monitoring the bone healing process. |
| Name | Type | Description |
|---|---|---|
| Bone Morphogenetic Protein 2 | DRUG | 12 mg recombinant BMP-2 combined with an injection of 1-2 g collagen type 1. |
| Autologous bone graft | PROCEDURE | Autologous bone graft in connection with bone docking operation. |
Inclusion Criteria: * Hospitalised for autologous bone graft based on Ilizarow treatment. * Age between 20 and 70 years. Exclusion Criteria: * Rheumatoid osteoarthritis * Malignant disease * Current hormone treatment (glucocorticoid, parathyreoidea, thyreoidea) * Pregnancy * Abuse of drugs and al...
Bone Morphogenetic Protein 2 is an investigational small molecule being developed for bone degenerative changes, including osteoarthritis and degenerative disorder of bone. It is intended to address musculoskeletal conditions where bone degeneration occurs. The drug is currently in clinical development and has not been approved by regulatory authorities.
Bone Morphogenetic Protein 2 is being developed by Medtronic plc, a medical technology company traded on the New York Stock Exchange under the ticker MDT. The company is conducting clinical research on this investigational drug for bone degenerative changes.
Bone Morphogenetic Protein 2 is in Phase 1 clinical development. It is an investigational drug and has not been approved by the FDA or other regulatory agencies. The drug is still in early-stage clinical trials to evaluate its safety and efficacy for bone degenerative changes.
Bone Morphogenetic Protein 2 has one completed clinical trial, NCT01690260, titled 'Parallel Study Between BMP-2 and Autologous Bone Graft After Ilizarow Treatment'. This Phase 1 trial enrolled 41 participants in Denmark and was a randomized, double-blind, controlled study. The trial is completed, and no active trials are currently listed.
Yes, Bone Morphogenetic Protein 2 is commonly referred to as BMP-2. The clinical trial NCT01690260 uses the abbreviation BMP-2 in its title. This alternative name is frequently used in medical literature and clinical research to refer to the same investigational drug.